United Therapeutics (NASDAQ:UTHR) CEO Sells $5,376,810.00 in Stock

Posted by Brian Himes on May 21st, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $565.98, for a total value of $5,376,810.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,929,547.74. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $1.94 during midday trading on Thursday, hitting $565.87. 418,827 shares of the company’s stock were exchanged, compared to its average volume of 477,460. The stock’s 50 day moving average price is $562.18 and its 200-day moving average price is $510.32. The firm has a market cap of $24.02 billion, a P/E ratio of 20.89, a PEG ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.63 earnings per share. On average, analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics during the 4th quarter valued at $293,418,000. Avoro Capital Advisors LLC lifted its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

UTHR has been the subject of a number of research analyst reports. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

View Our Latest Stock Report on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.